PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer
| Autor: | Kim M. Smits, Véronique Winnepenninckx, Frank J. P. Hoebers, Eric Thunnissen, Boudewijn Brans, Roy I. Lalisang, Pascal Kempers, Michel Öllers, Ernst-Jan M. Speel, Anne-Marie C. Dingemans, Philippe Lambin, Danielle J. Vugts, Ronald Boellaard, Hugo J.W.L. Aerts, Wouter van Elmpt, Aniek J.G. Even, Ludwig Dubois, Dirk De Ruysscher, Judith van Loon |
|---|---|
| Přispěvatelé: | RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapie, Promovendi ODB, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Faculteit FHML Centraal, Pathologie, MUMC+: DA Pat Pathologie (9), RS: GROW - R2 - Basic and Translational Cancer Biology, Radiology and nuclear medicine, CCA - Imaging |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine EGFR-INHIBITION Lung Neoplasms medicine.medical_treatment Cetuximab 0302 clinical medicine Carcinoma Non-Small-Cell Lung PLUS CETUXIMAB Hematology Middle Aged ErbB Receptors Oncology Head and Neck Neoplasms 030220 oncology & carcinogenesis Toxicity SURVIVAL Immuno-PET Female Zr-89-cetuximab medicine.drug RADIOTHERAPY EXPRESSION CARCINOMA EGFR Antineoplastic Agents 03 medical and health sciences Phase I trial medicine Carcinoma Humans Radiology Nuclear Medicine and imaging In patient Lung cancer neoplasms Aged business.industry Cancer Pet imaging 1ST-LINE CHEMOTHERAPY medicine.disease digestive system diseases Radiation therapy 030104 developmental biology Positron-Emission Tomography Zirconium MONOCLONAL-ANTIBODIES business Nuclear medicine GROWTH-FACTOR RECEPTOR |
| Zdroj: | Radiotherapy and Oncology, 122(2), 267-273. Elsevier Ireland Ltd Radiotherapy and Oncology. Elsevier Ireland Ltd van Loon, J, Even, A J G, Aerts, H J W L, Öllers, M, Hoebers, F, van Elmpt, W, Dubois, L, Dingemans, A-M C, Lalisang, R I, Kempers, P, Brans, B, Winnepenninckx, V, Speel, E-J, Thunnissen, E, Smits, K M, Boellaard, R, Vugts, D J, De Ruysscher, D & Lambin, P 2016, ' PET imaging of zirconium-89 labelled cetuximab : A phase I trial in patients with head and neck and lung cancer ', Radiotherapy and Oncology . https://doi.org/10.1016/j.radonc.2016.11.020 |
| ISSN: | 0167-8140 |
| DOI: | 10.1016/j.radonc.2016.11.020 |
| Popis: | Background and purpose: PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer (89)zr-cetuximab and to assess tumour uptake.Methods: Two dose schedules were used; two consecutive doses of 60 MBq Zr-89-cetuximab or a single dose of 120 MBq, both preceded by 400 mg/m(2) of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours.Results: Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with administration of 89Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR) > 1 was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose schedules. There was a trend for higher TBR at intervals > 5 days after injection.Conclusions: Both presented 89Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60 MBq, with a minimum time interval for scanning of 6 days. (C) 2016 Elsevier Ireland Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect